GENEDX HOLDINGS CORP CLASS A (WGS)
Health Care · Genomic diagnostics and sequencing · NASDAQ
GeneDx is a genomic intelligence platform using whole-genome sequencing and AI-powered interpretation to diagnose rare diseases, analyze cancers, and support precision medicine across clinical and research settings.
What GENEDX HOLDINGS CORP CLASS A does
GeneDx Holdings Corp. operates a genomic intelligence platform providing clinical and research sequencing tests, with products and services spanning rare disease diagnosis, cancer genomics, and reproductive health. The company acquired Fabric Genomics and is integrating AI-powered capabilities into its test interpretation and clinical workflows. GeneDx serves healthcare providers, hospitals, laboratories, and research institutions, generating revenue from test orders, partnerships, and data services through a subscription and pay-per-test model.
Themes: ["Genomic sequencing / rare disease diagnosis","AI and machine learning for variant interpretation","Oncology / cancer genomics","Reproductive health / prenatal testing","Clinical laboratory diagnostics","Precision medicine and genomic data"]
Fundamentals
- Price$69.39 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return-23.0% as of 2026-07-09 close
- Net margin-17.6% as of 2026-07-10
- Gross margin+69.6% as of 2026-07-10
- ROE-27.5% as of 2026-07-10
- Debt / equity0.38 as of 2026-07-10
- Revenue growth (YoY)+34.1% as of 2026-07-10
- Revenue CAGR (3y)+22.1% SEC XBRL
- Beta2.00 as of 2026-07-10
Key risks (from latest filing)
["Reimbursement and coverage decisions by third-party payors are critical to revenue sustainability, with potential for denials or reduced reimbursement rates affecting business profitability","FDA regulatory actions and changes to medical laboratory regulations could restrict test offerings or impose operational requirements that increase costs","The company is unprofitable with negative net margins (-17.58%), generating operating losses that require sustained capital availability and successful scaling to achieve profitability"]
Competitors & peers
- Invitae
- Myriad Genetics
- Guardant Health (cancer genomics)
- Tempus AI (cancer and clinical data)
- Ambry Genetics
- PreCision Medicine
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.